Should I taper Mounjaro or stop suddenly?

What the evidence actually says about tapering

There is no randomised controlled trial comparing tirzepatide tapering against planned abrupt stopping in terms of weight, appetite, or cardiometabolic outcomes. The evidence that does exist — SURMOUNT-4 — compared continued treatment against withdrawal, without testing different stopping strategies. [1] Any clinician who tells you definitively that tapering is better than stopping is inferring from pharmacology, not citing a trial.

That inference may be reasonable — and tapering is common clinical practice — but it should be presented as clinical judgement, not evidence. The honest answer is that we do not know whether tapering produces meaningfully better outcomes than structured stopping with a maintenance plan.

The pharmacological case for tapering

Tirzepatide has a half-life of approximately five days. This means that even without formal tapering, drug levels decline gradually over four to five weeks after the last dose — not suddenly. There is no sharp "cliff" when you stop. The body is not experiencing abrupt withdrawal in the physiological sense. What tapering does is extend this gradual decline further — a slower slide rather than a slightly faster one.

The theoretical benefit is that a slower decline gives the patient more time to adapt behaviourally before appetite fully returns. Whether this theoretical benefit translates to materially different clinical outcomes is unknown.

When tapering makes most practical sense

Dose reduction for cost or side-effect management: if you are on 10 mg or 15 mg and want to reduce dose to 5 mg as a step toward stopping (or as a sustainable long-term maintenance approach), this is a clinically rational strategy — though not evidenced as superior to maintenance dosing at therapeutic levels.

When you have time: if your stopping timeline is flexible — no surgery, no supply crisis — a one-dose-level reduction for four to six weeks before stopping is a low-risk approach that may make the appetite transition slightly gentler.

When you do not have time: if stopping is necessary quickly — surgery, supply failure, clinical decision — the absence of a taper is not dangerous. Plan the maintenance structure aggressively instead.

When sudden stopping is appropriate

If a serious adverse effect is suspected — severe abdominal pain, signs of pancreatitis, severe allergic reaction — stop immediately. Do not taper. Get assessed. [2] The MHRA guidance is clear that clinical concerns override dosing protocols.

If you are stopping because of cost and the choice is between a partial taper or full cessation, stopping and managing the exit with a proper plan is clinically preferable to half-measures that run out partway through.

What actually determines outcomes

The evidence consistently points to the same factors as the primary determinants of post-stopping outcomes, regardless of how you stop: lean mass preservation through resistance training during treatment; protein-anchored nutrition; consistent weight monitoring after stopping; a pre-agreed review threshold; and whether blood pressure and diabetes medication have been appropriately adjusted. [1,3]

None of these factors are changed by the tapering decision. A well-planned sudden stop outperforms an unplanned taper every time. The question of taper versus no taper is secondary to whether the stopping plan is complete.

A GLP-1 Exit Strategy Review addresses the complete stopping plan — including whether tapering is appropriate for your specific situation — rather than treating it as the primary decision.